Global Chimeric Antigen Receptor Cell Therapy Market Growth (Status and Outlook) 2023-2029

Global Chimeric Antigen Receptor Cell Therapy Market Growth (Status and Outlook) 2023-2029

LPI (LP Information)' newest research report, the “Chimeric Antigen Receptor Cell Therapy Industry Forecast” looks at past sales and reviews total world Chimeric Antigen Receptor Cell Therapy sales in 2022, providing a comprehensive analysis by region and market sector of projected Chimeric Antigen Receptor Cell Therapy sales for 2023 through 2029. With Chimeric Antigen Receptor Cell Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Chimeric Antigen Receptor Cell Therapy industry.

This Insight Report provides a comprehensive analysis of the global Chimeric Antigen Receptor Cell Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Chimeric Antigen Receptor Cell Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Chimeric Antigen Receptor Cell Therapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Chimeric Antigen Receptor Cell Therapy and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Chimeric Antigen Receptor Cell Therapy.

The global Chimeric Antigen Receptor Cell Therapy market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Chimeric Antigen Receptor Cell Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Chimeric Antigen Receptor Cell Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Chimeric Antigen Receptor Cell Therapy is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Chimeric Antigen Receptor Cell Therapy players cover Amgen Inc, Autolus Therapeutics Plc, Beijing Immunochina Medical Science & Technology Co Ltd, Bellicum Pharmaceuticals Inc, Bristol-Myers Squibb Co, bluebird bio Inc, CARsgen Therapeutics Ltd, Celgene Corp and Cell Medica Ltd, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Chimeric Antigen Receptor Cell Therapy market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Monotherapy
Combination Therapy

Segmentation by application
Acute Leukemia
Non-hodgkin's Lymphoma
Multiple Myeloma
Transplant Rejection
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Amgen Inc
Autolus Therapeutics Plc
Beijing Immunochina Medical Science & Technology Co Ltd
Bellicum Pharmaceuticals Inc
Bristol-Myers Squibb Co
bluebird bio Inc
CARsgen Therapeutics Ltd
Celgene Corp
Cell Medica Ltd
Cellular Biomedicine Group Inc
Celularity Inc
Celyad SA
Daiichi Sankyo Co Ltd
Fosun Pharmaceutical AG
Gilead Sciences Inc
Guangzhou Anjie Biomedical Technology Co Ltd
Hangzhou Converd Co Ltd
Hebei Senlang Biotechnology Inc Ltd
HRAIN Biotechnology Co Ltd
Juno Therapeutics Inc
Kite Pharma Inc
Nanjing Legend Biotech Co Ltd
NantKwest Inc
Nkarta Inc
Novartis AG
Ono Pharmaceutical Co Ltd
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Sorrento Therapeutics Inc
Takara Bio Inc

Please note: The report will take approximately 2 business days to prepare and deliver.